Adaptive Biotech

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the best growth stocks under $20 to buy. On May 5, Adaptive Biotechnologies reported strong Q1 2026 results, with total revenue reaching $70.9 million, a 35% increase year-over-year. The company

A study accepted to ML4H 2025 explores whether sequence-based models trained on large-scale T-cell activation data can improve prediction of T cell receptor recognition, a longstanding challenge in computational immunology with implications for cancer and

Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong one-year stock gains.

ADAPTIVE BIOTECH ($ADPT) posted quarterly earnings results on Thursday, May 1st. The company reported earnings of -$0.20 per share, beating estimates of -$0.30 by $0.10. The company also reported revenue of $52,440,000, beating estimates of $43,532,141 by

The Human Rights Campaign (HRC) Foundation's 2025 Corporate Equality Index (CEI) is the national benchmark on corporate policies, practices and benefits impacting LGBTQ+ employees. Each year, the CEI is a primary driving force for LGBTQ+ workplace inclusi

Facing cancer takes courage. It also requires collaboration: patients and their physicians working together to gain the information they need throughout the treatment journey. At Adaptive, we are proud to develop advanced testing methods that can provide

Pride Month is an opportunity to celebrate the history and progress made by the lesbian, gay, bisexual, transgender, queer (LGBTQ+) community, while also reflecting on the ongoing challenges faced today. As the lead of the Adaptive Pride employee resource

In the ever-evolving field of immunology, the study of T-cell responses to various exposures is pivotal for unraveling the complexities of immune health and advancing new therapies that use these natural defenses. T cells, through their unique receptors,

In honor of Multiple Myeloma Awareness Month, we sat down with Dr. Hamza Hashmi, a hematologist-oncologist from Memorial Sloan Kettering Cancer Center, to understand how his family's personal experience with cancer has influenced his approach to treating

In 2021, Susan Bobulsky sat down with Dr. Luciano Costa to learn about the initial results from the phase 2 MRD response-Adapted Sequential ThERapy (MASTER) trial. The trial evaluated daratumumab (Darzalex), carfilzomib (Kyprolis), lenalidomide (Revlimid)